Roivant Sciences presents a high-risk, high-reward biotech investment defined by a shrinking cash buffer ($1.2B as of 2026Q1, down 82% from $6.5B in 2023Q4) and escalating R&D spending ($202M in 2026Q1, up 67% from 2023Q4).
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has collapsed 95% from $28.9M in 2023Q4 to $1.4M in 2026Q1, while operating losses widened to -$366M, reflecting escalating R&D and SG&A costs.
Roivant Sciences is expanding its brepocitinib development program with a new Phase 2b/3 trial in Lichen Planopilaris (LPP), indicating potential growth in its pipeline.
The U.S. FDA has accepted Roivant's New Drug Application for brepocitinib in dermatomyositis and granted Priority Review, targeting a potential launch by Q3 2026.
Positive Phase 3 study results for batoclimab in Thyroid Eye Disease (TED) could drive investor confidence and future revenue streams.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.33-10.1% vs -$0.30 | $1M-29.9% vs $2M |
Q2 2026 May 20, 2026 | -$0.28+3.5% vs -$0.29 | $3M-26.2% vs $3M |
Q1 2026 Feb 6, 2026 | -$0.24+19.9% vs -$0.30 | $2M-60.6% vs $5M |
Q4 2025 Nov 10, 2025 | -$0.20+36.9% vs -$0.32 | $2M-72.0% vs $6M |
Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $36.31, for a total value of $7,262,000.00. Following the completion of the sale, the chief executive officer directly owned 999,154 shares
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript
Roivant Sciences NASDAQ: ROIV reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis (NIU), an inflammatory eye disease that can result in vision loss.
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2 studies. Brepocitinib also achieved statistically significant and clinically meaningful benefit on all key secondary endpoints, including measurements of sustained steroid-free quiescence at Week 48, chorioretinal vascular leakage, resolution of macular edema and patient-reported visual functioning. These results were achieved despite a substantially more aggressive steroid taper than precedent NIU trials.
Benchmark ROIV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Roivant Sciences Ltd. (ROIV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $38.88 | $28.09B | -105.25 | -71.57% | -3534.88% | -5.33% | — | |
| $14.48 | $2.18B | -4.03 | — | — | -2271.87% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $291.31 | $514.68B | 49.87 | 8.57% | 15.68% | — | 2.26% |
Roivant Sciences Ltd. (ROIV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Roivant Sciences Ltd. (ROIV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 20, 2026·SEC
Apr 2, 2026·SEC
Get notified when ROIV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Roivant Sciences Ltd. (ROIV) stock FAQ — growth, dividends, profitability & financials explained
Roivant Sciences Ltd. (ROIV) reported $7.5M in revenue over the trailing twelve months. Revenue was $8.3M in fiscal year 2025. That is 88% less than the $67.7M of fiscal year 2019.
Roivant Sciences Ltd. (ROIV) revenue fell by 67.6% over the trailing twelve months, compared with the twelve months before.
No. Roivant Sciences Ltd. (ROIV) reported a net loss of $266.2M over the trailing twelve months.
Roivant Sciences Ltd. (ROIV) had a return on equity (ROE) of -5.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
Roivant Sciences Ltd. (ROIV) had negative free cash flow of $814.0M over the trailing twelve months.
